Philip P. Rossetti

Phil Rossetti is a member of the Corporate Department and practices corporate and securities law, with an emphasis on:

• Mergers and acquisitions 

• Emerging companies 

• Private equity

• Venture capital financings 

• Public offerings

Mr. Rossetti handles merger and acquisition transactions for private and public companies. He serves as counsel for private and publicly traded clients in a broad range of technology, life sciences, and other industry sectors. He regularly advises early stage and venture-backed companies, particularly in the technology sector, providing counsel on formational issues, protection of technology, financings, and employment matters.

Mr. Rossetti also serves as counsel for a number of venture capital firms in connection with their portfolio investments.

Mr. Rossetti has been recognized as a:

• Leader in Corporate/M&A in the 2014 - 2019 editions of Chambers USA and Private Equity/Venture Capital Investment by Chambers USA 2011. Clients praise his "pragmatic" advice and ability to "exercise the kind of judgment that we would expect from a business perspective." Chambers USA has also stated that Mr. Rossetti “is very good at seeing things from a client's perspective and providing balanced advice.”

• Recommended lawyer for Mergers, Acquisitions and Buyouts: M&A Mega Deals, Venture Capital and Emerging Companies by The Legal 500 US 2012

Mr. Rossetti regularly represents companies in merger and acquisition transactions, including public company and private company acquisitions and sales and cross-border transactions. Representative transactions include advising: 

• Mimecast in its acquisitions of Ataata and Solebit Labs
• Mainspring Capital Partners in its acquisition of Aero Spray
• Cytel in its sale to New Mountain Partners
• Mainspring Health Solutions in its sale to Accruent
• Constant Contact's US$1.1 billion sale to Endurance International 
• Watts Water Technologies' US$264.5 million acquisition of Aerco International
• Assurex Health in its sale to Myriad Genetics
• Intact Medical in its sale to Medtronic
• Epirus Biopharmaceuticals' reverse public merger with Zalicus
• Palladin Consumer Retail Partners' acquisition of KT Health, LLC (provider of KT Tape), Aerosoles (women's shoes), and Harry's of London (men's shoes)
• Dairy Farmers of America's acquisition of Oakhurst Dairy, a national dairy farmer-owned cooperative
• Zipcar in its US$500 million sale to Avis Budget Group
• Constant Contact in its acquisition of CardStar and Single Platform
• Memento in its sale to Fidelity Information Systems
• Micronetics in its sale to Mercury Computer Systems
• Network Engines in its sale to Unicom
• NitroSecurity, Inc. in its sale to McAfee, Inc.
• Unica Corporation in its US$480 million sale to IBM*
• NewRiver in its sale to Broadridge Financial Solutions*
• Broadband Access Systems in its US$2.25 billion sale to ADC Telecommunications* 
• Spring Tide Networks in its US$1.5 billion sale to Lucent Technologies* 
• NetCore Systems in its US$575 million sale to Tellabs, Inc.* 
• Webline in its US$325 million sale to Cisco* 
• Network Engines in its acquisitions of TidalWire and Alliance Systems* 
• Nordica NV in its acquisition of Rollerblade, Inc.*
• Open Development Corporation in its sale to Glenayre Technologies* 
• The management team of the Colt Firearms Division of Colt Industries, Inc. in its US$90 million buyout*
• Decision Resources in its sale to private equity firms* 
• Home Made Brand Foods in its sale to a private equity firm*

Mr. Rossetti has served as counsel in many initial and follow-on public offerings, on behalf of issuers and underwriters, the latter including JP Morgan H&Q, Oppenheimer, and CIBC World Markets. Offerings include: Epirus Biopharmaceuticals, Constant Contact, Citrix Systems, Dialogic Corporation, Bottomline Technologies, NetScout Systems, CrossComm Corporation, Network Engines, eMerge Interactive, Predictive Systems, Alpha Industries, Cree Research, C-Cor.net, Cannondale, PSC, LCC International, ChiRex, GelTex Pharmaceuticals, EPIX Medical, Momenta Pharmaceuticals, Progenics, Starent Networks, AutoImmune, Alpha-Beta Technology, and Transcend Therapeutics.

*Matter handled prior to joining Latham

• The Latham US IPO Guide -  July 11, 2016